Here are the S-1 registration statements from Jupiter Neurosciences, Inc. (JUNS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow JUNS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JUNS filings page.
Jupiter Neurosciences, Inc. is registering 16,000,000 shares of common stock for resale by YA II PN, LTD (Yorkville) under a Standby Equity Purchase Agreement (SEPA). These “Advance Shares” may be issued at Jupiter’s discretion through one or more Advances.
The SEPA provides up to $20.0 million in potential equity financing, of which $2.8 million has already been raised through earlier sales and related convertible notes. As of June 17, 2026, Jupiter had 48,224,110 shares outstanding; if all 16,000,000 registered shares were issued, they would represent about 24.9% of total shares and 31.6% of non‑affiliate shares, meaning meaningful potential dilution to existing holders.
Jupiter is a clinical-stage pharmaceutical company developing JOTROL™, an enhanced resveratrol formulation targeting central nervous system disorders including Parkinson’s disease, and commercializing its Nugevia™ longevity and wellness supplement line. The company expects SEPA proceeds to primarily support a Phase 2 Parkinson’s trial, expand direct‑to‑consumer Nugevia marketing, and fund general corporate purposes.